European Union Drugs Agency - EUDA

ℹ️ Ketamine in Europe: what are the latest trends and risks?

In our recent webinar, we explored how ketamine is becoming more visible in parts of Europe’s drug market, and what this means for public health and monitoring efforts.

The discussion covered emerging patterns of use, developments in illicit markets and the health risks linked to non-medical use.

For healthcare professionals, the session also highlighted the importance of recognising ketamine-related health problems and ensuring appropriate care.

🎥 Watch the full recording here: https://www.euda.europa.eu/media-library/euda-webinar-ketamine-europe_en

🎉 The 200th issue of Drugnet Europe is out!

📘 Since 1996, this newsletter has followed the evolution of Europe’s drug situation and reported on key developments, publications and milestones in the life of the agency under four Directors.

The current issue features the latest updates, including:
🔹 European Drug Report 2026 launch (9 June)
🔹 New miniguide on dual disorders
🔹 Upcoming webinars and latest recordings
🔹 Research opportunities and vacancies

🔍 Read more here: https://mailchi.mp/euda/drugnet-europe-200-may2026

📩 Subscribe to Drugnet Europe: https://europa.us7.list-manage.com/subscribe?u=7661463396b2fc9d763392225&id=3f011a8795

If your work focuses on drug use, prevention and crime, a new EU funding opportunity is now available!

🔎 Under Horizon Europe Cluster 3 — Civil Security for Society, applications are open for the topic ‘Crime prevention approaches, online and off-line, tackling the nexus between addictions and crime’.

The focus is on strengthening understanding, testing new approaches and bringing together research, innovation and practice to support more effective responses, particularly for young people at risk.

📢 For those working in research, policy or practice, this is an opportunity to contribute to stronger, evidence-based prevention approaches.

Explore the Cluster 3 — Civil Security for Society Work Programme:
https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/cluster-3-civil-security-society_en

🔗 Follow open calls on the EU Funding and Tenders Portal: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-CL3-2026-01-FCT-04?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-CL3-2026-01-FCT-04&isExactMatch=true&status=31094501,31094502,31094503

For an overview of drug-related opportunities under Horizon Europe, read our news item:
https://www.euda.europa.eu/news/2026/horizon-europe-2026%E2%80%932027-new-eu-funding-opportunities-drug-related-research_en

💻 You can still join our webinar happening tomorrow! ⬇

Ketamine use is changing in Europe, with growing concerns around health harms linked to non-medical use.

This session will cover developments in the ketamine market and associated risks.

For healthcare professionals, it will also highlight the importance of recognising ketamine-related health problems and ensuring appropriate care.

📅 27 May 2026 │ 14:00–15:00 Lisbon time (WEST) │ 15:00–16:00 (CEST)

👉 Register: https://www.euda.europa.eu/event/2026/05/euda-webinar-ketamine-europe_en

💻 EUDA webinar: Ketamine in Europe

Join us for a discussion on the European ketamine market, with a focus on emerging trends and health-related harms linked to non-medical use.

We will present findings from the latest Ketamine in Europe situation report, covering developments in illicit markets and associated risks.

We will explore:

✅ Key trends in the European ketamine market
✅ Health risks linked to non-medical use
✅ Insights from recent analysis and monitoring

📅 Date and time: 27 May 2026 │ 14:00–15:00 Lisbon time (WEST) │ 15:00–16:00 (CEST)

👉 Register now: https://www.euda.europa.eu/event/2026/05/euda-webinar-ketamine-europe_en

How we understand drug trends depends on close cooperation with national experts.

🌍 Across the EU, as well as Norway and Türkiye, national focal points collect, analyse and share data on drug use, markets and related harms. Together, they form the Reitox network, which connects national evidence with the work of the EU Drugs Agency.

To ensure this cooperation works effectively, each focal point is assessed on how it contributes to the EUDA’s tasks and how it manages its processes, data and collaboration at national and European levels.

The first full cycle of these assessments has now been completed, with the final visit taking place in Madrid last week. All focal points assessed have met the conditions for a successful outcome.

👏 We would like to thank and congratulate them for their strong engagement and commitment throughout this process.

👉 Learn more about how we work together with national focal points:
https://www.euda.europa.eu/publications/work-programmes-and-strategies/reitox-alliance-operating-framework_en

Getting the right care can be more complex when mental health and substance use problems occur in the same individual.

🧩 People with dual disorders often face fragmented services, delayed diagnosis and gaps in support. A new EUDA miniguide brings together current evidence and practice in this area and outlines key elements of effective, integrated responses.

It highlights approaches such as early detection, combined treatment, trauma-informed care and better training for professionals. Improving coordination between services can help ensure that people receive appropriate support wherever they first seek help.

The miniguide also points to uneven access to services across Europe and the need for stronger links between mental health and substance use systems, better data and sustained investment.

🔗 https://www.euda.europa.eu/publications/mini-guides/dual-disorders_en

Since the start of Russia’s military aggression against Ukraine in February 2022, the European Union has put in place a comprehensive response, with actions in the Justice and Home Affairs domain playing an important role.

🤝 Across the EU Justice and Home Affairs Agencies’ Network, our nine agencies participate in this response by assisting Member States and partners, and by contributing to support for people affected by the war, particularly those displaced from Ukraine.

The 5th edition of our Joint paper provides an overview of this work.

📄 Find out more here: https://www.euda.europa.eu/drugs-library/eu-justice-and-home-affairs-agencies-network-contribution-eu-solidarity-ukraine_en

❓ How can workplaces better support recovery and social inclusion for people with substance use problems?

Today in Zagreb, we partnered with our Croatian national focal point to host a Reitox Academy focused on workplace support policies, employment and recovery.

💡 Reitox Academies bring together experts from across Europe, including EU Member States, Norway and Türkiye, to exchange knowledge, training and practical experience on drug-related issues. Through the Reitox network, countries connect data, expertise and approaches to support an evidence-based response. The EUDA also supports work in this area by improving knowledge on the interaction between drug policy and labour policy.

During the session, discussions focus on prevention in the workplace, social reintegration and the role of employment in supporting long-term recovery, including examples from Germany, Ireland and Finland, as well as on how policies can reduce stigma and strengthen support systems.

🤝 HZJZ - Hrvatski zavod za javno zdravstvo

👉 Learn more about how the Reitox network supports cooperation across Europe: https://www.euda.europa.eu/publications/work-programmes-and-strategies/reitox-alliance-operating-framework_en

💻 EUDA webinar: Ketamine in Europe

Join us for a discussion on the European ketamine market, with a focus on emerging trends and health-related harms linked to non-medical use.

We will present findings from the latest Ketamine in Europe situation report, covering developments in illicit markets and associated risks.

We will explore:

✅ Key trends in the European ketamine market
✅ Health risks linked to non-medical use
✅ Insights from recent analysis and monitoring

📅 Date and time: 27 May 2026 │ 14:00–15:00 Lisbon time (WEST) │ 15:00–16:00 (CEST)

👉 Register now: https://www.euda.europa.eu/event/2026/05/euda-webinar-ketamine-europe_en